Coherus Oncology Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Coherus Oncology stock has a consensus rating of "Strong Buy" and an average price target of $7.80. The average 1-year stock price forecast is 449.30% higher than the current stock price, while the lowest is $4.00 (+181.69%) and the highest is $12 (+745.07%).

Price Target: $7.80 (+449.30%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$4.00	$7.80	$7.00	$12
Change	+181.69%	+449.30%	+392.96%	+745.07%

Analyst Ratings

The average analyst rating for Coherus Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	4	4	4	4	5
Buy	1	1	1	1	1	1
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	6	6	6	6	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Nedelcovych TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 28, 2026
Jason McCarthy Maxim Group	Maxim Group	Buy Maintains $4	Buy	Maintains	$4	+181.69%	May 13, 2026
Jay Olson Oppenheimer	Oppenheimer	Buy Maintains $10	Buy	Maintains	$10	+604.23%	May 12, 2026
Douglas Tsao H.C. Wainwright	H.C. Wainwright	Buy Reiterates $7	Buy	Reiterates	$7	+392.96%	May 12, 2026
Paul Jeng Guggenheim	Guggenheim	Buy Initiates $12	Buy	Initiates	$12	+745.07%	May 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

73.03M

from 42.17M

73.16%

from 42.17M

Revenue Next Year

100.06M

from 73.03M

37.02%

from 73.03M

EPS This Year

-0.75

from -1.36

EPS Next Year

-1.02

from -0.75

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	326.55M	211.04M	257.24M	26.39M	42.17M	73.03M
Revenue Growth	-31.37%	-35.37%	21.89%	-89.74%	59.81%	73.16%
Gross Profit	268.96M	140.96M	98.25M	17.66M	28.36M	46.01M
Gross Margin	82.36%	66.79%	38.19%	66.93%	67.24%	63.00%
Operating Income	-263.86M	-256.88M	-193.20M	-189.05M	-176.43M	-156.34M
Net Income	-287.10M	-291.75M	-237.89M	28.51M	168.02M	-158.74M
EPS	-	-	-	-	-1.36	-0.75
Free Cash Flow	-60.97M	-186.86M	-69.86M	-13.17M	-68.72M	-102.00M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	140.1M
Avg	73.0M
Low	57.7M

Revenue Growth

Revenue Growth	2026	2027	2028
High	232.2%
Avg	73.2%
Low	36.9%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.75
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-